Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04815005 · ClinicalTrials.gov registry record
HoFH, the International Clinical Collaborators Registry
A clinical trial of Homozygous Familial Hypercholesterolemia, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 4
- Study locations
NCT04815005 is a study of Homozygous Familial Hypercholesterolemia that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 1,000 participants, above the 86-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (1063% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT04815005, a study of Homozygous Familial Hypercholesterolemia, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.
Conditions Studied
Interventions
- OTHER Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Study Locations (4)
Other
- Department of Vascular Medicine, Amsterdam UMC - Amsterdam
- Department of Medicine, Division of Lipidology and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town - Cape Town
- c. Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand - Johannesburg
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04815005
The ClinicalTrials.gov registry entry for NCT04815005 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 86-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (1063% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence. is the first listed.
NCT04815005 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04815005 about?
NCT04815005 is a clinical study titled "HoFH, the International Clinical Collaborators Registry". Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD)....
What is the current status of trial NCT04815005?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2017-01-24. Estimated completion is 2026-12-31.
What conditions does trial NCT04815005 study?
This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.
What interventions are being tested in trial NCT04815005?
The interventions under investigation include: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence. (OTHER).
Who is sponsoring clinical trial NCT04815005?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04815005 being conducted?
This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
RECRUITING
-
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
RECRUITING · Phase 3
-
LOWER: Lomitapide Observational Worldwide Evaluation Registry
RECRUITING
-
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
COMPLETED · Phase 2
-
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.